← Evidence map

ArticleTherapeutic innovation & regulatory science2026

Perspectives on the Use of a Bayesian Approach in Designing Seamless Phase 2/3 Clinical Trials with Dose Selection, Early Stopping for Futility and Efficacy, or Sample Size Re-estimation.

Natalia Muehlemann et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Perspectives on the Use of a Bayesian Approach in Designing Seamless Phase 2/3 Clinical Trials with Dose Selection, Early Stopping for Futility and Efficacy, or Sample Size Re-estimation. | OpenQuestion